Northern Trust’s Grace Therapeutics GRCE Stock Holding History

Northern Trust’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-349	Closed	-$41K	–	4281
2019 Q4	$41K	Buy	+349	New	+$34.5K	﹤0.01%	4085

Other funds holding GRCE

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JLBC

J.L. Bainbridge & Co Sarasota, Florida $1.27B AUM 26.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Northern Trust's GRCE Position: Q1 2020 in Review

Northern Trust sold out of Grace Therapeutics (GRCE) in Q1 2020, closing a stake of 349 shares — an estimated $41K sold.

Northern Trust first reported a position in GRCE in Q4 2019 and held it in 1 quarter. The position peaked at $41K in Q4 2019. 26 funds tracked by Wall St. Rank hold GRCE as of Q1 2020.

Northern Trust reported no remaining Grace Therapeutics position as of Q1 2020 after selling out during the quarter.
Northern Trust sold 349 Grace Therapeutics shares in Q1 2020, an estimated $41K.
Northern Trust first reported a position in Grace Therapeutics in Q4 2019 and held it in 1 quarter.
Northern Trust's Grace Therapeutics position peaked at $41K in Q4 2019.
26 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2020.

Based on Northern Trust's 13F filing for Q1 2020, filed 14 May 2020.